Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/151121
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRomaguera, Rafael-
dc.contributor.authorGómez Hospital, Joan Antoni-
dc.contributor.authorSánchez Elvira, Guillermo-
dc.contributor.authorGómez Lara, Josep-
dc.contributor.authorFerreiro, José Luis-
dc.contributor.authorRoura, Gerard-
dc.contributor.authorGracida Blancas, Montserrat-
dc.contributor.authorHoms, Silvia-
dc.contributor.authorTeruel, Luís M.-
dc.contributor.authorCequier Fillat, Àngel R.-
dc.date.accessioned2020-02-25T09:01:28Z-
dc.date.available2020-02-25T09:01:28Z-
dc.date.issued2013-02-18-
dc.identifier.issn0896-4327-
dc.identifier.urihttp://hdl.handle.net/2445/151121-
dc.description.abstractObjectives: To assess the usefulness of the MGuard stent in patients with ST‐segment elevation myocardial infarction (STEMI) in whom a high thrombus burden persists after manual aspiration. Background: In some patients with STEMI, a high thrombus burden may persist after manual aspiration. These patients may be at high risk of distal embolization and therefore impaired myocardial reperfusion. The MGuard is a novel mesh‐covered stent designed to minimize thrombus embolization. Methods: Single‐arm, prospective registry of patients with STEMI and high thrombus burden after aggressive thrombus aspiration treated with the MGuard stent. High thrombus burden was defined as thrombus burden grade 4 or 5 according to the TIMI score. Lesions with a side branch ≥2 mm and patients with cardiogenic shock were not included. The study end‐points were proportion of final TIMI 3 flow, normal myocardial blush, and complete ST‐segment resolution. Results: Fifty‐six patients were included. After MGuard stent implantation >85% of cases had thrombus score = 0. Final TIMI 3 flow was achieved in 82% of cases, normal myocardial blush in 55%, and complete ST‐segment resolution in 59%. Occlusion of a side branch (<2 mm) occurred in 2 cases (3.5%), embolization to a distal branch in 5 cases (8.9%), and transient no‐reflow in 4 cases (7.1%). Major adverse cardiac events rate at 9 months was 3.6%, including 1 definite acute stent thrombosis and 1 target‐vessel revascularization. Conclusions: The MGuard stent may be useful to prevent distal embolization in patients with STEMI and high thrombus burden despite mechanical aspiration.-
dc.format.extent7 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherWiley Hindawi Publishing-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1111/j.1540-8183.2013.12011.x-
dc.relation.ispartofJournal of Interventional Cardiology, 2013, vol. 26, num. 1, p. 1-7-
dc.relation.urihttps://doi.org/10.1111/j.1540-8183.2013.12011.x-
dc.rightscc-by (c) Romaguera, Rafael et al., 2013-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Ciències Clíniques)-
dc.subject.classificationInfart de miocardi-
dc.subject.classificationPròtesis de Stent-
dc.subject.otherMyocardial infarction-
dc.subject.otherStents (Surgery)-
dc.titleMGuard mesh-covered stent for treatment of ST-segment elevation myocardial infarction with high thrombus burden despite manual aspiration-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec633061-
dc.date.updated2020-02-25T09:01:28Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
633061.pdf185.54 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons